8-K
filed May 10, 2023, 7:59 PM ET
ticker LEXX
CIK 0001348362
other
confidence high
sentiment neutral
materiality 0.15
Lexaria Bioscience shareholders reelect all 6 director nominees and approve all proposals at annual meeting
Lexaria Bioscience Corp.
- All six director nominees elected: Bunka (96.5%), Docherty (96.3%), Baxter (74.3%), McKechnie (95.7%), Reese (96.2%), Turkel (97.6%).
- Stock option repricing approved with 68.9% of votes cast (1,529,271 for; 677,686 against).
- Amendment to Incentive Equity Plan (max shares) approved with 88.6%; evergreen formula addition approved with 63.1%.
- Appointment of Malone Bailey LLP as auditors ratified with 96.4% (3,249,199 for).
- Ratification of directors' past actions approved with 90.4%.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lexaria Bioscience Corp. shareholders approved To Appoint Malone Bailey LLP as Auditors at the 2023-05-09 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-09
Exact text from the filing
To Appoint Malone Bailey LLP as Auditors 3,249,199 105,067 17,758 96.4%
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lexaria Bioscience Corp. shareholders approved To Approve the Stock Option Repricing at the 2023-05-09 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-05-09
Exact text from the filing
To Approve the Stock Option Repricing 1,529,271 677,686 12,429 1,152,638 68.9%
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lexaria Bioscience Corp. shareholders approved To Ratify the lawful actions of the directors for the past year at the 2023-05-09 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-09
Exact text from the filing
To Ratify the lawful actions of the directors for the past year 2,005,926 156,382 57,145 1,152,571 90.4%
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lexaria Bioscience Corp. shareholders approved To Approve the Amendment to the Maxim Number of Shares Issuable pursuant to the Incentive Equity Plan at the 2023-05-09 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-05-09
Exact text from the filing
To Approve the Amendment to the Maxim Number of Shares Issuable pursuant to the Incentive Equity Plan 1,965,779 249,519 4,155 1,152,571 88.6%
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lexaria Bioscience Corp. shareholders approved Election of Directors at the 2023-05-09 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-09
Exact text from the filing
To Elect Chris Bunka as a director 2,141,964 77,489 1,152,571 96.5% To Elect John Docherty as a director 2,137,546 81,907 1,152,571 96.3% To Elect Nicholas Baxter as a director 1,648,288 571,165 1,152,571 74.3% To Elect Ted McKechnie as a director 2,123,869 95,584 1,152,571 95.7% To Elect Albert Reese Jr. as a director 2,134,837 84,683 1,152,504 96.2% To Elect Dr. Catherine Turkel as a director 2,165,426 54,027 1,152,571 97.6%
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Lexaria Bioscience Corp. shareholders approved To Approve the Addition of an Evergreen Formula to the Incentive Equity Plan at the 2023-05-09 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-05-09
Exact text from the filing
To Approve the Addition of an Evergreen Formula to the Incentive Equity Plan 1,400,723 709,940 108,790 1,152,571 63.1%
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.